1- (2,3-Dichlorophenyl) piperazine Hydrochloride CAS 119532-26-2 Aripiprazole Intermediate Purity>99.0% (HPLC)
Ndị nrụpụta na-eweta etiti nke Aripiprazole na ịdị ọcha dị elu
Aripiprazole API CAS 129722-12-9
1- (2,3-Dichlorophenyl)piperazine Hydrochloride CAS 119532-26-2
7-Hydroxy-3,4-Dihydro-2(1H) -Quinolinone CAS 22246-18-0
7- (4-Bromobutoxy) -3,4-Dihydro-2 (1H) -Quinolinone CAS 129722-34-5
Aha Chemical | 1- (2,3-Dichlorophenyl)piperazine Hydrochloride |
Ụdị okwu | 2,3-DCPP HCl;1- (2,3-Dichlorophenyl) piperazine HCl;Aripiprazole EP adịghị ọcha B;Njikọ dị na Aripiprazole C |
Nọmba CAS | 119532-26-2 |
Nọmba CAT | RF-PI2268 |
Ọnọdụ Ahịa | Na Akụrụngwa, Ikike Mmepụta 30 MT / Ọnwa |
Usoro ihe omimi | C10H12Cl2N2·HCl |
Ibu molekụla | 267.58 |
Ebe Na-agbaze | 245.0 ~ 247.0 ℃ |
Nchekwa & Mmetụta | Hygroscopic.Okpomọkụ gburugburu |
Solubility na Mmiri | Soluble na Mmiri |
Ụdị | Ruifu Chemical |
Ihe | Nkọwapụta |
Ọdịdị | Ọcha ma ọ bụ Gbanyụọ-Ọcha ntụ ntụ |
Ụzọ ịdị ọcha / nyocha | > 99.0% (HPLC) |
Ọnwụ na ihicha | <0.50% |
Ihe fọdụrụ na mgbanye | <0.10% |
Otu adịghị ọcha | <0.50% |
Mgbakọta adịghị ọcha | <1.00% |
Ọla dị arọ (dị ka Pb) | ≤20ppm |
Spectrum infrared | Dabara na Ọdịdị |
Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
Ojiji | Ọkara nke Aripiprazole (CAS: 129722-12-9) |
ngwugwu: Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ
Ọnọdụ Nchekwa:Hygroscopic.Chekwaa pụọ na mmiri/mmiri na ihe ndị na-eme ihe na-ekpo ọkụ.Debe akpa ahụ nke ọma ma tinye ya na ọnọdụ dị jụụ, kpọrọ nkụ na nke ọma.Chekwaa n'okpuru gas inert
1- (2,3-Dichlorophenyl) piperazine Hydrochloride (CAS: 119532-26-2) bụ etiti dị mkpa nke Aripiprazole (CAS: 129722-12-9).Aripiprazole bụ ụdị ọhụrụ nke ihe nrụpụta quinoline soluble lipid nke ukwuu, njirimara ọgwụ ya bụ na ọ bụghị naanị postsynaptic dopamine D 2 antagonist, kamakwa presynaptic dopamine D 2 agonist, ọ nwekwara ike kpalie D 1, D 3, D 4 ndị na-anabata ya;ọ nwere mmetụta abụọ nke ntinye akụkụ ma ọ bụ onye na-anabata ihe na-anabata 5-HT 1A;o nwere ihe mmegide kpamkpam na onye nnabata 5-HT 2A.Njirimara a dị iche na ọgbọ mbụ, yana antipsychotics nke na-ahụ maka ọgbọ nke abụọ nke ọgwụ antipsychotic, ya mere a na-akpọ ya dopamine system stabilizer ma ọ bụ ọgbọ atọ antipsychotic.Ebe ọ bụ na a na-ere ya n'ahịa, a na-ejikarị ya na schizophrenia nke ụlọ ọgwụ, ọgwụgwọ ọrịa na-emetụta mmetụta na ọrịa uche ndị ọzọ.Dị ka akwụkwọ akụkọ si kwuo, aripiprazole nwere mmetụta dị ịrịba ama na schizophrenia nti na mgbaàmà na-adịghị mma na nchekasị, ịda mbà n'obi, ọrụ ọgụgụ isi, ebe nchekwa dị elu.A kọkwara na ọgwụ ahụ nwekwara ike ịgwọ ọrịa uche ndị ọzọ, dị ka nsogbu ọnọdụ uche manic episodes, senile dementia jikọtara na nsogbu uche, nsogbu nchekasị, nsogbu omume ụmụaka, ịda mbà n'obi.N'oge a,Bristol-Myers Squibb na Otsuka Pharmaceutical Company kwupụtara na European Union akwadola Abilify (aripiprazole) na ọgwụgwọ nke ngwa ndepụta schizophrenia.